ストックスクリーナーアプリを入手
725.72
4.21%
-31.88
プレマーケット:
727.15
1.43
+0.20%
Lilly Eli Co (LLY) 最新ニュース
Eli Lilly: Market Overreacted (NYSE:LLY) - Seeking Alpha
Is Eli Lilly And Co. (LLY) Splitting in the Near Future? - Yahoo Finance
Eli Lilly, Avago lead market cap stock movers on Monday - Investing.com
Eli Lilly and Company (NYSE:LLY) Trading Down 4.1%Here's What Happened - MarketBeat
Eli Lilly, Nvidia among Monday's market cap stock movers - Investing.com
Pain Management Therapeutics Market Is Expected To Reach Revenue Of USD 120.7 Bn By 2033, At 3.9% CAGR: Dimension Market Research. - GlobeNewswire Inc.
Lilly, Merck team with Purdue University to pioneer new drug production methods - FiercePharma
Pediatric Medicines Market May See a Big Move | Eli Lilly, Johnson & Johnson, Pfizer - openPR
Jim Cramer Says ‘Eli Lilly and Company (LLY)’s Drug Is Superior In Terms Of Weight Reduction At The Same Dose’ - Yahoo Finance
Jim Cramer on Eli Lilly and Company (LLY)’s Q4 2024 Performance: ‘Aren’t As Strong As Wall Street Was Hoping’ - Insider Monkey
Should You Buy the Dip in Eli Lilly Stock Right Now? - MSN
Eli Lilly Faces a Dramatic Stock Plunge! Is This Your Chance to Cash In? - Jomfruland.net
Eli Lilly Missed Sales Expectations Again. Should Investors Be Worried? - sharewise
Here’s Why Jim Sees Eli Lilly and Company (LLY) as a Long-Term Buy - Insider Monkey
Why Is Cliff Asness Bullish On Eli Lilly and Company (LLY)? - Insider Monkey
Eli Lilly Stock Tumbles on Slower-Than-Expected Weight Loss Drug Sales. Is This a Buying Opportunity? - The Motley Fool
Purdue, Lilly and Merck launch new manufacturing collaboration effort - Purdue Exponent
How Is The Market Feeling About Eli Lilly? - Benzinga
Leerink keeps Eli Lilly stock outperform on revenue growth - MSN
Meds made by Novo Nordisk, Pfizer, Eli Lilly among those up for Medicare price negotiations - Sherwood News
Leerink keeps Eli Lilly stock outperform on revenue growth By Investing.com - Investing.com Canada
Eli Lilly stock target cut, retains Buy rating on growth potential - MSN
Leerink Partners Reiterates Outperform Rating on Eli Lilly (LLY) - StreetInsider.com
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030 - 24/7 Wall St.
Purdue aims to speed evolution of pharma manufacturing in collaboration with Lilly and Merck - Purdue University
FDA Approves Expanded Use Of Eli Lilly's Ulcerative Colitis Drug For Crohn's Disease - Yahoo Finance
Pace quickens at the Eli Lilly and Co. Lebanon site - Lebanon Reporter
7MM Type 1 Diabetes Market Drug Forecast and Market Analysis 2023-2024 & 2033: Value to Reach $9.91 Billion - GlobeNewswire Inc.
Burney Co. Has $24.47 Million Stock Holdings in Eli Lilly and Company (NYSE:LLY) - MarketBeat
Could Donald Trump Make Eli Lilly Stock a No-Brainer Buy in 2025? - The Motley Fool
FDA approves Lilly’s Omvoh for Crohn’s disease - WISH TV Indianapolis, IN
Eli Lilly & Co. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Eli Lilly's Options: A Look at What the Big Money is Thinking - Benzinga
Here's How Much $1000 Invested In Eli Lilly 15 Years Ago Would Be Worth Today - Benzinga
Crohn’s Gets More Competitive As Lilly Lands Second Omvoh Okay - News & Insights
Lilly IBD biologic receives expanded US approval -January 16, 2025 at 11:01 am EST - Marketscreener.com
Lilly IBD biologic receives expanded US approval - European Pharmaceutical Review
Is Lilly Stock A Sell After Tumbling On Its Guidance Cut? - Investor's Business Daily
JPM25: The FDA’s future, AbbVie’s second thoughts and Lilly’s lesson - BioPharma Dive
Eli Lilly and Co. employees donate food and money to The Caring Center - Lebanon Reporter
Founders Grove Wealth Partners LLC Acquires New Position in Eli Lilly and Company (NYSE:LLY) - MarketBeat
Eli Lilly and Company (NYSE:LLY) Shares Acquired by Community Trust & Investment Co. - MarketBeat
Eli Lilly and Company (NYSE:LLY) Stock Unloaded Rep. Josh Gottheimer - MarketBeat
Rep. Josh Gottheimer Sells Eli Lilly and Company (NYSE:LLY) Stock - MarketBeat
US FDA approves expanded use of Lilly's bowel disease drug - Reuters
Today at JP Morgan: Spending Lilly’s billions, GSK’s Blenrep prepped, cautious optimism for China drug deals and a gene therapy breakout - FirstWord Pharma
Eli Lilly's SWOT analysis: stock poised for growth despite challenges - Investing.com
Eli Lilly Receives FDA Approval for Crohn’s Disease Treatment - The Wall Street Journal
FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease - Investors | Eli Lilly and Company
Stock Quote & Chart | Eli Lilly and Company - Investors | Eli Lilly and Company
Eli Lilly & Co. (LLY) Announces FDA Approval of Omvoh for Crohn's disease - StreetInsider.com
Eli Lilly is considering offering more Zepbound doses in vials at lower cost - STAT
Eli Lilly CEO on Trump, obesity drugs, and a guidance miss - STAT
Eli Lilly Adjusts Outlook, CEO David Ricks Explains Revenue Shortfall - Benzinga
Eli Lilly and Company (NYSE:LLY) Trading 0.7% HigherWhat's Next? - MarketBeat
Bernstein reiterates Eli Lilly stock outperform rating - Investing.com
Jim Cramer on Eli Lilly and Company (LLY): ‘There’s Been Some Mistakes’ - Insider Monkey
Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock - MSN
Eli Lilly Cuts Q4 Sales Forecast: ETFs to Buy on the Dip - Yahoo Finance
As Lilly Stock Tumble on GLP-1 Demand Worries, CEO Says All Is Well - MSN
Eli Lilly Gets Wall Street Backing After Tuesday’s Turmoil, Stock Rises Premarket As Retail Stays Bullish - MSN
5.27%
大文字化:
|
ボリューム (24 時間):